INTRODUCTION
Diabetes is one of the most common causes of peripheral neuropathy in the world. More than half of the diabetic patients have neuropathy, and more than half of the patients with peripheral neuropathy have diabetes. [1, 2] Diabetic neuropathy occurs in both type 1 and type 2 diabetes. This disorder may be manifested by polyneuropathy, mononeuropathy, or autonomic neuropathy. [3, 4] The symptoms of neuropathy depend on several factors; one of them is the type of nerves that are affected (sensory or motor). Damage to the motor nerve or decreasing sweating, constipation, diarrhea, and incontinence. [6, 8] The most common type of diabetic neuropathy is polyneuropathy. Toes are usually involved initially. When the neuropathy progresses, the symptoms move from the toes toward the foot and gradually toward the knee. [5] Diabetic autonomic neuropathy can involve multiple systems such as cardiovascular, digestive, and urogenital. [6] Autonomic neuropathy involving the cardiovascular system is one of the most important forms of autonomic dysfunction. [9] Vascular and neurological disorders are interrelated. The vascular system needs normal nervous system function and nervous system function dependents on adequate blood supply. In diabetic neuropathy, first pathological change in the small blood vessels is contraction of the muscular wall of the vessels. [1] As the disease progresses, neuropathy develops along with the progression of vascular abnormalities. Nervous system ischemia is one of the proven features of diabetic neuropathy. Vascular dilatation can lead to a significant improvement in the nerve tissue blood supply, which will coincide with the improvement in nerve conduction velocity. [10] Diabetes mellitus is associated with hypercoagulation state and increased viscosity of blood, resulting in insufficient blood supply in the level of small blood vessels. [11] In addition, rheological abnormalities of erythrocytes (such as reduced ductility and decreased oxygen binding capacity and increased accumulation) can also be responsible for reducing oxygen supply to tissue. [12] Pentoxifylline is a derivative of xanthine and is available with brand names of torental, pentox, pentoxine and artal (SPSS 18 (SPSS Software IBM, Inc., New York City, New York State, USA). It is in the group of nonselective phosphodiesterase inhibitors; it increases the intracellular cyclic adenosine monophosphate and activates protein kinase A. [13] Pentoxifylline is often prescribed as good tolerable medications for the improvement of peripheral blood flow defects. Pentoxifylline initially increases blood flow with a beneficial effect on the rheological properties of red blood cells and increases the oxygen content of the ischemic tissue. It also reduces the viscosity of plasma and blood. In addition, it prevents platelet aggregation, improves vascular dilatation by increasing prostacyclin, and has a special effect on immune responses through tumor necrosis factor (TNF)-α suppression. [14] There are no known cures for diabetic neuropathy, and therefore, treatment is only symptomatic. Pentoxifylline could theoretically be a beneficial treatment for diabetic sensory neuropathy, [15] but there is not enough evidence to prove its effectiveness. The purpose of this study was to investigate the effect of pentoxifylline in improving diabetic distal polyneuropathy.
METHODS
We did a double-blind, randomized placebo-controlled trial (IRCT2016051827965N1) from July 2016 to June 2017. We design a parallel trial. The study population included type 2 diabetic patients with distal polyneuropathy based on the Michigan Neuropathy Screening Instrument (MNSI). Inclusion criteria included a history of type 2 diabetes for more than 1 year, aged 40-75 years, symptom of distal polyneuropathy according to the MNSI, and glycosylated hemoglobin (HbA1c) between 8% and 10%. Exclusion criteria included systolic blood pressure above 160 mmHg, advanced diabetic retinopathy, history of heart failure, renal failure, liver failure, pregnancy and lactation, history of amputation, and those who have recently used gabapentin or nortriptyline (4 weeks before trial initiation).
We calculated the sample size of 30 patients in each group. The sample size was calculated based on the comparing means formula and the mean difference of 4, the standard deviations of 4 and 7.5, [16] the power of 80%, and the Type 1 error of 0.05.
Participants were selected from patients who referred to private clinics and government clinics in Qom, Iran. For eligible patients, after a brief introduction about the study (how they are implemented, the purpose of the study, the time of study, the potential benefits and risks of study, and the expression of ethical points), patients who completed the informed consent form were included in the study.
Finally, 60 eligible patients were included in the study. Concealed random allocation was done using a randomized block design. Sixty patients allocated randomly based on the block randomization method in a 1:1 ratio. We used block size four (AABB, ABAB, ABBA, BBAA, BABA, and BAAB), and the third block was randomly selected. One of the researchers who was not care-provider did the random allocation sequence, enrolled participants, and assigned participants to interventions. Care provider who assessed outcomes and participants was blind about allocation.
For each participant, a questionnaire including age, sex, height, weight, HbA1c, fasting blood sugar (FBS), duration of diabetes, duration of distal polyneuropathy, and MNSI was completed.
The MNSI has two Parts A and B. Part A was used to record symptoms of neuropathy and was completed by the patient, and Part B includes a clinical evaluation completed by a physician and only vibration test and ankle reflexes was used in this study. The questionnaire has high sensitivity (80%) and specificity (95%). [17] After confirmation of neuropathy by a physician, patients were randomly assigned into two intervention and control groups. The intervention group received pentoxifylline (400 mg twice daily) and Vitamin B1 (100 mg twice daily) and control group received Vitamin B1 (100 mg twice daily) and placebo (twice daily) for 2 months. The shape and packing of placebo and pentoxifylline were similar. Before and after intervention, the symptoms of distal polyneuropathy were recorded by MNSI, and the vibration threshold was investigated by diapason (128 Hz). The standard treatment for diabetes, blood pressure medications, and lipid-lowering drugs remained unchanged during the study.
All patients completed the trial. Medications were delivered to patients monthly. Patients returned empty drug blister pack at the end of each month to confirm the use of medications.
The Ethics Committee of Qom University of Medical Sciences approved this study (IR.MUQ.REC.1395.12) and written informed consent was obtained from the all participants. Data were analyzed using SPSS 18 software (SPSS Software IBM, Inc., New York City, New York State, USA), and the statistical significance level of P < 0.05. Paired t-test, unpaired t-test, Chi-square, and Fisher's exact test were used to compare groups for outcomes. ANCOVA test was performed to compare the after-intervention outcomes with control of preintervention values. The assumptions needed for analyses tests, such as normality, homogeneity of variance, and random independent samples, were established.
RESULTS
All 60 patients received intended treatment, and all were analyzed for the outcomes. No participant was excluded during the, and there was no loss to follow-up.
The mean age of patients was 57.1 ± 8.02 years. There was no significant difference between the two groups in regard to the baseline variables [ Table 1 ]. Seventy-five percent of patients taking any dose of statin (73.3% of intervention group and 76.7% of placebo group) (P = 0.76).
Blood pressure, body mass index, and blood glucose did not change significantly during the study [ Tables 2 and 3 ]. In the pentoxifylline group, the symptoms of peripheral neuropathy were significantly improved (P = 0.042).
Changes in neuropathy symptom [ Table 4 ] and physical examination [ Table 5 ] were also analyzed for each question. Changes were only significant for questions 6 (Does it hurt when the bed covers touch your skin?) and 12 (Do your legs hurt when you walk?).
DISCUSSION
The aim of this study was to evaluate the effects of pentoxifylline on distal diabetic neuropathy in patients with type 2 diabetes. In this study, MNSI questionnaire was used to evaluate the severity of polyneuropathy. There was no significant difference between the two groups in terms of initial variables. After the intervention, the mean score of the clinical symptoms decreased by 0.63 in the intervention group, whereas in the control group, the decrease was 0.13 and the difference was statistically significant (P = 0.046). However, there was no significant difference in the clinical examination between the two groups (P = 0.471).
Cohen and Harris first reported in 1987 that pentoxifylline was given to 8 patients for the treatment of neuropathy for 16 weeks; in 6 patients, neuropathy had improved; and in 2 patients, burning and numbness of the fingers improved perfectly, this effect was independent of the effect of the drug on blood glucose and renal function.
[15] Afterward, Mr. Kalmansohn et al. reported in 1988 an 80-year-old patient with a 5-year history of diabetic distal neuropathy who had reduced the symptoms of neuropathy 1 month after the onset of pentoxifylline, and 4 months after, the drug has reached its maximum effect. Mr. Kalmansohn et al. said in his report that pentoxifylline is likely to increase blood flow to small vessels and improve neuropathy due to reduced blood viscosity and increased flexibility of red blood cells. [18] In 1990, Cohen et al. studied 21 patients with diabetic neuropathy and treated 12 patients with 400 mg pentoxifylline, three times a day for 12 weeks and 9 patients with placebo. The severity of diabetic neuropathy was measured by a questionnaire. This study showed that pentoxifylline had no advantage over placebo in reducing symptoms of the diabetic neuropathy. [19] In 1991, Cohen and Mathews treated 20 patients with diabetic neuropathy by pentoxifylline and 20 patients by placebo. After 6 months of treatment, the two groups did not have any significant difference in terms of visual analog scores, nerve conduction, and neuropathic examination. [16] In 1992, Rendell and Bamisedun treated 24 patients with diabetic neuropathy with pentoxifylline for 6 months, of which 17 reported a decrease in symptoms. In this study, the skin blood flow was also examined by Doppler sonography, skin blood flow increased significantly after treatment, and the sensation threshold also improved after 6 months. [20] In 1997, Lee et al. treated 25 patients with pentoxifylline and 25 patients with placebo; Lee reported there was no significant change in touch sense threshold, numbness and pain, after 6 weeks of treatment. [17] In 2009, Laczy et al. also treated 77 patients with diabetic neuropathy with injections form of pentoxifylline and pentosan polysulfate and 12 patients with saline for 5 days. The threshold of vibrational sensation after the treatment was significantly improved in the intervention group compared with the placebo group. [10] Despite the fact that for over 30 years, the treatment of neuropathy with pentoxifylline has passed, but so far, no good study has been done. Only five clinical trials for the use of this drug were found that a study was based on the In animal studies, Flint et al. also looked at the effect of pentoxifylline on diabetic neuropathy in mice, which the results of the study showed that pentoxifylline could improve neuropathy by the improvement of nerves tissue blood flow. [21] Most studies have suggested that the effect of pentoxifylline is by reducing the viscosity of the blood and increasing the resiliency of red blood cells and thereby increasing the blood flow of the nerves. [18] Satoh et al. suggested that pentoxifylline can improve diabetic neuropathy by reducing TNF-α and reducing free radicals. [22] In another study, Garcia et al. showed that pentoxifylline reduces inflammatory factors such as TNF-α, interleukin-6, and inducible nitric oxide synthase, which can improve diabetic neuropathy by reducing inflammation.
[13] The lack of changes in blood glucose control (FBS, HbA1c, 2-h postprandial blood sugar) after study and the lack of changes in patient's blood pressure in the present study can show that the mechanism of pentoxifylline effect is independent of the effect on these factors.
The main limitation of the study was low number of patients in the intervention and placebo groups.
CONCLUSION
The results of this study and its comparison with previous studies showed that pentoxifylline could be effective in reducing the symptoms of diabetic distal neuropathy. However, further evidence is needed to prove this effect. Long-term clinical trials are recommended to investigate the long-term effects of this drug. 
